Mark Pimentel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mark Pimentel has a total of 486 co-authors. Here are the top co-authors by number of shared publications:
Walter Morales
Medically Associated Science and Technology (MAST) Program, Cedars-Sinai
52 shared publicationsStacy Weitsman
Medically Associated Science and Technology (MAST) Program, Cedars-Sinai
49 shared publications- Christopher Chang
GI Motility Program, Cedars-Sinai Medical Center, Los Angeles, California, USA
30 shared publications Ali Rezaie
Medically Associated Science and Technology (MAST) Program, Cedars-Sinai
25 shared publicationsGabriela Leite
Medically Associated Science and Technology (MAST) Program, Cedars- Sinai, Los Angeles, USA
22 shared publicationsGene Kim
21 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 28 (1) , 29
Do Multi-Omics Approaches Improve the Diagnosis of Microbial Overgrowth Syndromes?
Purpose of Review: This review investigates how advances in breath testing (BT), small bowel (SB) culture, metagenomics, metatranscriptomics, transcriptomics and proteomics are reshaping the definition and diagnosis of small intestinal bacterial overgrowth (SIBO). It also discusses whether SIBO should be redefined as part of a larger group of microbial overgrowth syndromes. Recent Findings: Recent studies identify distinct hydrogen-, methane-, and hydrogen sulfide-associated overgrowth phenotypes, termed SIBO, intestinal methanogen overgrowth (IMO), and intestinal sulfide overproduction (ISO). SB sampling shows that these conditions involve different microbial patterns and functional activity, symptoms, and host responses. Quantitative shotgun metagenomics provides greater taxonomic and functional resolution than culture, while metatranscriptomics reveals active microbial pathways. On top of that, host transcriptomics and proteomics contribute to the better understanding of the predominant microbial effects in host cellular mechanisms in each of the distinct small bowel overgrowth types. Summary: SIBO has been increasingly identified as a disorder of microbial ecology and function rather than bacterial quantity alone. Integrating BT with SB sampling and multi-omics approaches may improve classification, clarify symptom mechanisms, and support a more individualized treatment, although standardized methods and further clinical validation remain necessary.
- 7 September 2026
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 28 (1) , 29
Open AccessDo Multi-Omics Approaches Improve the Diagnosis of Microbial Overgrowth Syndromes?
Purpose of Review: This review investigates how advances in breath testing (BT), small bowel (SB) culture, metagenomics, metatranscriptomics, transcriptomics and proteomics are reshaping the definition and diagnosis of small intestinal bacterial overgrowth (SIBO). It also discusses whether SIBO should be redefined as part of a larger group of microbial overgrowth syndromes. Recent Findings: Recent studies identify distinct hydrogen-, methane-, and hydrogen sulfide-associated overgrowth phenotypes, termed SIBO, intestinal methanogen overgrowth (IMO), and intestinal sulfide overproduction (ISO). SB sampling shows that these conditions involve different microbial patterns and functional activity, symptoms, and host responses. Quantitative shotgun metagenomics provides greater taxonomic and functional resolution than culture, while metatranscriptomics reveals active microbial pathways. On top of that, host transcriptomics and proteomics contribute to the better understanding of the predominant microbial effects in host cellular mechanisms in each of the distinct small bowel overgrowth types. Summary: SIBO has been increasingly identified as a disorder of microbial ecology and function rather than bacterial quantity alone. Integrating BT with SB sampling and multi-omics approaches may improve classification, clarify symptom mechanisms, and support a more individualized treatment, although standardized methods and further clinical validation remain necessary.
- Open Access
- 22 July 2026
- Published by MDPI AG in Preprints.org
Exenatide Is Associated with Superior Gastrointestinal Motility Slowing Among GLP-1 Receptor Agonists
Objectives: Exenatide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that slows gastrointestinal (GI) motility. Whether exenatide produces clinically detectable GI motility slowing in real-world practice — and how this compares to other GLP-1 RAs — has not been systematically evaluated. We addressed this question using federated, electronic health record (EHR) data. Further, we present clinical data on vurolenatide, a long-acting variant of exenatide, in patients with short bowel syndrome (SBS), a condition defined by nutritional insufficiency where reducing GI motility could be beneficial to patient outcomes. Methods: We queried de-identified EHR data on the nSights platform to identify treatment episodes for exenatide, semaglutide, and tirzepatide among patients with documented GI hypermotility. Anti-constipation medication prescriptions, body weight, and HbA1c trajectories were compared between pre- and post-treatment periods. Given exenatide’s GI potency, we enrolled 9 SBS patients in a Ph 1b/2a study looking at vurolenatide, dosed subcutaneously every 2 weeks. Safety, tolerability, total urine output, and total stool output were the primary endpoints with the latter serving as a metric for GI motility. Results: We identified patients on exenatide (n=387), semaglutide (10,315), and tirzepatide (5,095) and found the prevalence of anti-constipation prescriptions increased significantly in the exenatide cohort over 12 months (11.09% to 18.62%; p=6.75×10⁻⁴). No significant change was detected with semaglutide (17.54% to 17.70%, p=0.734), and tirzepatide was associated with a decrease in use (18.72% to 14.84%, p<0.001). Exenatide did not impact body weight (-0.5%, p=0.299), compared to semaglutide (-3.95%, p<0.001) and tirzepatide (-8.44%, p<0.001), nor impact HbA1c (-0.02 %-points, p=0.926), compared to semaglutide (-0.26 %-points, p<0.001) and tirzepatide (-0.56 %-points, p<0.001). Consistent with exenatide’s potency at slowing GI motility, biweekly dosing of vurolenatide in human SBS patients showed immediate reduction in total stool output and in the number of bowel movements patients experienced. Conclusions: Exenatide is associated with potent slowing of GI motility in retrospective analysis of EHR data as well as in prospective treatment of SBS patients. This real-world signal proxies the mechanism underlying vurolenatide in SBS and provides a first-in-kind pharmacoepidemiological basis for GLP-1 RA–mediated modulation of GI motility.
- 22 July 2026
- Published by MDPI AG in Preprints.org
Open AccessExenatide Is Associated with Superior Gastrointestinal Motility Slowing Among GLP-1 Receptor Agonists
Objectives: Exenatide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that slows gastrointestinal (GI) motility. Whether exenatide produces clinically detectable GI motility slowing in real-world practice — and how this compares to other GLP-1 RAs — has not been systematically evaluated. We addressed this question using federated, electronic health record (EHR) data. Further, we present clinical data on vurolenatide, a long-acting variant of exenatide, in patients with short bowel syndrome (SBS), a condition defined by nutritional insufficiency where reducing GI motility could be beneficial to patient outcomes. Methods: We queried de-identified EHR data on the nSights platform to identify treatment episodes for exenatide, semaglutide, and tirzepatide among patients with documented GI hypermotility. Anti-constipation medication prescriptions, body weight, and HbA1c trajectories were compared between pre- and post-treatment periods. Given exenatide’s GI potency, we enrolled 9 SBS patients in a Ph 1b/2a study looking at vurolenatide, dosed subcutaneously every 2 weeks. Safety, tolerability, total urine output, and total stool output were the primary endpoints with the latter serving as a metric for GI motility. Results: We identified patients on exenatide (n=387), semaglutide (10,315), and tirzepatide (5,095) and found the prevalence of anti-constipation prescriptions increased significantly in the exenatide cohort over 12 months (11.09% to 18.62%; p=6.75×10⁻⁴). No significant change was detected with semaglutide (17.54% to 17.70%, p=0.734), and tirzepatide was associated with a decrease in use (18.72% to 14.84%, p<0.001). Exenatide did not impact body weight (-0.5%, p=0.299), compared to semaglutide (-3.95%, p<0.001) and tirzepatide (-8.44%, p<0.001), nor impact HbA1c (-0.02 %-points, p=0.926), compared to semaglutide (-0.26 %-points, p<0.001) and tirzepatide (-0.56 %-points, p<0.001). Consistent with exenatide’s potency at slowing GI motility, biweekly dosing of vurolenatide in human SBS patients showed immediate reduction in total stool output and in the number of bowel movements patients experienced. Conclusions: Exenatide is associated with potent slowing of GI motility in retrospective analysis of EHR data as well as in prospective treatment of SBS patients. This real-world signal proxies the mechanism underlying vurolenatide in SBS and provides a first-in-kind pharmacoepidemiological basis for GLP-1 RA–mediated modulation of GI motility.
- Open Access
- 29 June 2026
- Published by American Society for Microbiology in mSystems
- Vol. 11 (7) , e0045826
Transcriptomics profiles in intestinal sulfide overproduction, small intestinal bacterial overgrowth, and intestinal methanogen overgrowth
Despite advances in identifying distinct microbial profiles linked to intestinal sulfide overproduction (ISO), small intestinal bacterial overgrowth (SIBO), and intestinal methanogen overgrowth (IMO), differences in host small bowel (SB) gene expression remain unexplored. Therefore, we compared host gene transcriptomics in SB biopsies from subjects with IMO, ISO, and SIBO. Separately, SB transcriptomics in rats gavaged with hydrogen sulfide (H 2 S) producers were also analyzed. ISO subjects exhibited unique transcriptomics profiles. ISO (≥1.5 parts per million [ppm] H 2 S) broadly affected genes linked to H₂S toxicity, such as electron transport chain and redox balance genes, while there were fewer significant effects on gene expression in IMO and SIBO. Rat data supported ISO findings, including dysregulation of mitochondrial respiration, redox balance, water homeostasis, immune response, and gut motility. IMPORTANCE: Intestinal sulfide overproduction (ISO), intestinal methanogen overgrowth (IMO), and small intestinal bacterial overgrowth (SIBO) are conditions associated with higher levels of breath hydrogen sulfide and methane, respectively, and higher bacterial colony counts on small bowel aspirate cultures. While these conditions correlate with gastrointestinal symptoms, the cellular mechanisms involved when analyzed either separately or concomitantly are not well understood. Here, we aimed to explore changes in human small bowel transcriptomics in ISO, IMO, and/or SIBO, and to investigate if changes in ISO reflect those seen in models of rats gavaged with known hydrogen sulfide producers. The results demonstrate that each condition is unique and has its own transcriptomics profile, with ISO showing a greater effect on the host, which was partially validated by transcriptomic analyses in the small bowel of rats gavaged with hydrogen sulfide-producing bacteria. This study supports the need for individualized therapeutic strategies for each condition in the future.
- 29 June 2026
- Published by American Society for Microbiology in mSystems
- Vol. 11 (7) , e0045826
Open AccessTranscriptomics profiles in intestinal sulfide overproduction, small intestinal bacterial overgrowth, and intestinal methanogen overgrowth
Despite advances in identifying distinct microbial profiles linked to intestinal sulfide overproduction (ISO), small intestinal bacterial overgrowth (SIBO), and intestinal methanogen overgrowth (IMO), differences in host small bowel (SB) gene expression remain unexplored. Therefore, we compared host gene transcriptomics in SB biopsies from subjects with IMO, ISO, and SIBO. Separately, SB transcriptomics in rats gavaged with hydrogen sulfide (H 2 S) producers were also analyzed. ISO subjects exhibited unique transcriptomics profiles. ISO (≥1.5 parts per million [ppm] H 2 S) broadly affected genes linked to H₂S toxicity, such as electron transport chain and redox balance genes, while there were fewer significant effects on gene expression in IMO and SIBO. Rat data supported ISO findings, including dysregulation of mitochondrial respiration, redox balance, water homeostasis, immune response, and gut motility. IMPORTANCE: Intestinal sulfide overproduction (ISO), intestinal methanogen overgrowth (IMO), and small intestinal bacterial overgrowth (SIBO) are conditions associated with higher levels of breath hydrogen sulfide and methane, respectively, and higher bacterial colony counts on small bowel aspirate cultures. While these conditions correlate with gastrointestinal symptoms, the cellular mechanisms involved when analyzed either separately or concomitantly are not well understood. Here, we aimed to explore changes in human small bowel transcriptomics in ISO, IMO, and/or SIBO, and to investigate if changes in ISO reflect those seen in models of rats gavaged with known hydrogen sulfide producers. The results demonstrate that each condition is unique and has its own transcriptomics profile, with ISO showing a greater effect on the host, which was partially validated by transcriptomic analyses in the small bowel of rats gavaged with hydrogen sulfide-producing bacteria. This study supports the need for individualized therapeutic strategies for each condition in the future.
- Open Access
- 2 February 2026
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 60 (5) , 406-417
Real-world Study of Three-gas Breath Testing Nationwide and the Association With Symptoms
Goals and Background: Hydrogen (H 2 ) breath testing (BT) is used to diagnose small intestinal bacterial overgrowth (SIBO), and methane (CH 4 ) to diagnose constipation. Recently, a third microbially derived gas, hydrogen sulfide (H 2 S), was added to BT and associated with diarrhea. Here, we assess a 3-gas BT nationwide, comparing the results to gastrointestinal (GI) symptoms. Study: Consecutive subjects (N=6000) undergoing 3-gas at-home BT were asked to complete a symptom questionnaire. Substrate choice (glucose or lactulose) was at physician’s discretion. H 2 , CH 4, and H 2 S levels, and presence/absence of SIBO (≥20 ppm rise in H 2 within 90 min), intestinal methanogen overgrowth (IMO) (≥10 ppm CH 4 ), and intestinal sulfide overproduction (ISO, defined here as ≥2 ppm H 2 S) were compared with symptom severity. Gas interactions and symptoms’ correlations were determined using machine learning (Uniform Manifold Approximation and Projection [UMAP]). Results: A total of 3004 subjects who completed breath tests and primary questions were included. Bloating was the most common reason for BT. More subjects reported severe or very severe symptoms for bloating (52.9%) than diarrhea (17.8%), constipation (17.1%), or abdominal pain (17.1%). SIBO positivity was more common using lactulose (27%) versus glucose (7.3%). Higher H 2 levels correlated with more severe diarrhea ( P =0.031), and CH 4 levels correlated with constipation ( P =0.002). Higher H 2 S levels correlated with more severe diarrhea ( P P =0.003), and abdominal pain ( P =0.01). UMAP revealed that H 2 S levels increased symptom severity, and ISO (alone or with SIBO/IMO) drove greater diarrhea, urgency, bloating, and overall severity, with highest pain and severity in ISO alone. Conclusions: H 2 , CH 4 , and H 2 S are associated with unique symptoms: CH 4 with constipation and H 2 S with diarrhea and a greater overall symptom severity. Glucose appears less sensitive than lactulose, suggesting it could potentially miss some symptomatic patients.
- 2 February 2026
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 60 (5) , 406-417
Open AccessReal-world Study of Three-gas Breath Testing Nationwide and the Association With Symptoms
Goals and Background: Hydrogen (H 2 ) breath testing (BT) is used to diagnose small intestinal bacterial overgrowth (SIBO), and methane (CH 4 ) to diagnose constipation. Recently, a third microbially derived gas, hydrogen sulfide (H 2 S), was added to BT and associated with diarrhea. Here, we assess a 3-gas BT nationwide, comparing the results to gastrointestinal (GI) symptoms. Study: Consecutive subjects (N=6000) undergoing 3-gas at-home BT were asked to complete a symptom questionnaire. Substrate choice (glucose or lactulose) was at physician’s discretion. H 2 , CH 4, and H 2 S levels, and presence/absence of SIBO (≥20 ppm rise in H 2 within 90 min), intestinal methanogen overgrowth (IMO) (≥10 ppm CH 4 ), and intestinal sulfide overproduction (ISO, defined here as ≥2 ppm H 2 S) were compared with symptom severity. Gas interactions and symptoms’ correlations were determined using machine learning (Uniform Manifold Approximation and Projection [UMAP]). Results: A total of 3004 subjects who completed breath tests and primary questions were included. Bloating was the most common reason for BT. More subjects reported severe or very severe symptoms for bloating (52.9%) than diarrhea (17.8%), constipation (17.1%), or abdominal pain (17.1%). SIBO positivity was more common using lactulose (27%) versus glucose (7.3%). Higher H 2 levels correlated with more severe diarrhea ( P =0.031), and CH 4 levels correlated with constipation ( P =0.002). Higher H 2 S levels correlated with more severe diarrhea ( P P =0.003), and abdominal pain ( P =0.01). UMAP revealed that H 2 S levels increased symptom severity, and ISO (alone or with SIBO/IMO) drove greater diarrhea, urgency, bloating, and overall severity, with highest pain and severity in ISO alone. Conclusions: H 2 , CH 4 , and H 2 S are associated with unique symptoms: CH 4 with constipation and H 2 S with diarrhea and a greater overall symptom severity. Glucose appears less sensitive than lactulose, suggesting it could potentially miss some symptomatic patients.
- 21 November 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (4) , 1044-1047
Performance of an Artificial Intelligence-Powered Smartphone Application in Identifying Gluten-free Foods for Individuals With Celiac Disease
INTRODUCTION: Gluten-free diet (GFD) adherence is critical for individuals with celiac disease but is often hindered by food labeling inconsistencies and limited dietary support. METHODS: We evaluated an AI-powered smartphone application's performance in classifying the GFD compatibility of packaged foods. Compatibility was assessed by gastroenterology-focused registered dietitians. RESULTS: Of 100 products (1,884 ingredients), dietitians classified 64 as GFD-compatible, of which only 37.5% (24/64) displayed a gluten-free label. The application demonstrated 99% and 99.8% accuracy at the product and ingredient level, respectively. DISCUSSION: With rigorous evaluation, AI-powered tools may support dietary adherence for patients with celiac disease.
- 21 November 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (4) , 1044-1047
Performance of an Artificial Intelligence-Powered Smartphone Application in Identifying Gluten-free Foods for Individuals With Celiac Disease
INTRODUCTION: Gluten-free diet (GFD) adherence is critical for individuals with celiac disease but is often hindered by food labeling inconsistencies and limited dietary support. METHODS: We evaluated an AI-powered smartphone application's performance in classifying the GFD compatibility of packaged foods. Compatibility was assessed by gastroenterology-focused registered dietitians. RESULTS: Of 100 products (1,884 ingredients), dietitians classified 64 as GFD-compatible, of which only 37.5% (24/64) displayed a gluten-free label. The application demonstrated 99% and 99.8% accuracy at the product and ingredient level, respectively. DISCUSSION: With rigorous evaluation, AI-powered tools may support dietary adherence for patients with celiac disease.
- Open Access
- 1 November 2025
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 38 (6)
Lessons learned from physician-performed high-resolution esophageal manometries
Summary: High-resolution esophageal manometry (HRM) is the gold standard test for evaluation and diagnosis of esophageal motility disorders. While the Chicago Classification offers a standardized protocol for performing and interpreting HRM studies, it does not provide guidance on catheter placement techniques, nor the specific skillset required to conduct the test. At most centers nationally and globally, HRMs are performed by a trained nurse or medical technician. However, in selected centers, physicians perform HRMs alongside a clinical care assistant. Direct physician involvement in performing HRM offers unique clinical insights that can potentially enhance diagnostic accuracy, procedural efficiency, and patient experience. Based on our more than two-decade experience with physician-performed HRMs, we share various tips and techniques to provide step-by-step guidance on performing a high-quality HRM. In addition, we provide reflections from our experience on several benefits of physician-performed manometries including continued continuity of care, real-time interpretation with ability to perform adjunctive testing, and improved patient tolerance.
- 1 November 2025
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 38 (6)
Open AccessLessons learned from physician-performed high-resolution esophageal manometries
Summary: High-resolution esophageal manometry (HRM) is the gold standard test for evaluation and diagnosis of esophageal motility disorders. While the Chicago Classification offers a standardized protocol for performing and interpreting HRM studies, it does not provide guidance on catheter placement techniques, nor the specific skillset required to conduct the test. At most centers nationally and globally, HRMs are performed by a trained nurse or medical technician. However, in selected centers, physicians perform HRMs alongside a clinical care assistant. Direct physician involvement in performing HRM offers unique clinical insights that can potentially enhance diagnostic accuracy, procedural efficiency, and patient experience. Based on our more than two-decade experience with physician-performed HRMs, we share various tips and techniques to provide step-by-step guidance on performing a high-quality HRM. In addition, we provide reflections from our experience on several benefits of physician-performed manometries including continued continuity of care, real-time interpretation with ability to perform adjunctive testing, and improved patient tolerance.
- Open Access
- 22 September 2025
- Published by Wolters Kluwer Health in Current Opinion in Gastroenterology
- Vol. 41 (6) , 399-408
Modern concepts of small intestinal bacterial overgrowth
Purpose of review: Small intestinal bacterial overgrowth (SIBO) has been a recognized condition for more than half a century. Early descriptions of SIBO were based on the concept of colonic bacteria “backing up” into the small intestine. This was based on techniques using unprotected aspiration catheters and earlier culture techniques. Recent advances in breath testing, small bowel sampling, culture techniques, and next generation sequencing have helped expand our understanding of SIBO. Recent findings: “SIBO” is now understood to encompass at least three different types of overgrowth including SIBO, intestinal methanogen overgrowth (IMO) and intestinal sulfide overproduction (ISO). Each has their own unique microbial profile. In addition, next generation sequencing has revealed that SIBO is not a migration of colonic flora into the small intestine, but rather overgrowth of two predominant species/strains from phylum Proteobacteria (Escherichia coli and Klebsiella). Lastly, results from next generation sequencing of the stool and small intestinal microbiomes have validated breath testing as a diagnostic tool. Summary: Together, these advances have allowed the identification of key microbes in overgrowth syndromes, uncovering their relationships to conditions such as irritable bowel syndrome, and paving the way for the development of novel customized treatment options in the future.
- 22 September 2025
- Published by Wolters Kluwer Health in Current Opinion in Gastroenterology
- Vol. 41 (6) , 399-408
Open AccessModern concepts of small intestinal bacterial overgrowth
Purpose of review: Small intestinal bacterial overgrowth (SIBO) has been a recognized condition for more than half a century. Early descriptions of SIBO were based on the concept of colonic bacteria “backing up” into the small intestine. This was based on techniques using unprotected aspiration catheters and earlier culture techniques. Recent advances in breath testing, small bowel sampling, culture techniques, and next generation sequencing have helped expand our understanding of SIBO. Recent findings: “SIBO” is now understood to encompass at least three different types of overgrowth including SIBO, intestinal methanogen overgrowth (IMO) and intestinal sulfide overproduction (ISO). Each has their own unique microbial profile. In addition, next generation sequencing has revealed that SIBO is not a migration of colonic flora into the small intestine, but rather overgrowth of two predominant species/strains from phylum Proteobacteria (Escherichia coli and Klebsiella). Lastly, results from next generation sequencing of the stool and small intestinal microbiomes have validated breath testing as a diagnostic tool. Summary: Together, these advances have allowed the identification of key microbes in overgrowth syndromes, uncovering their relationships to conditions such as irritable bowel syndrome, and paving the way for the development of novel customized treatment options in the future.
- Open Access
- 5 September 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (3) , 707-720
Relationship Between Hypothyroidism, Risk of Small Intestinal Bacterial Overgrowth, and Duodenal Microbiome Alterations
Context: There is an association between hypothyroidism and small intestinal bacterial overgrowth (SIBO), but the exact mechanistic link between these 2 conditions is not fully elucidated. Objective: We evaluate the incidence and risks of subsequently developing SIBO, and changes in small bowel microbial populations, in subjects with hypothyroidism or autoimmune thyroiditis. Design and Outcome Measures: Duodenal aspirates from REIMAGINE study subjects with a history of hypothyroidism (hypothyroid group, N = 49) and controls (N = 323) underwent 16S rRNA sequencing (MiSeq, Illumina); a subset also underwent metagenomic sequencing (NovaSeq6000, Illumina). Separately, the TriNetX Analytics platform was used to evaluate 10-year cumulative incidences and relative risk (RR) of developing SIBO in subjects with hypothyroidism (unspecified etiology [HUE]), and a subset with autoimmune thyroiditis, vs propensity score matched control groups. Results: Among REIMAGINE subjects, SIBO prevalence was higher in the hypothyroid group (32.65%) vs controls (15.17%). In the TriNetX analysis, 10-year cumulative incidences of SIBO were higher in HUE (RR = 2.20) and autoimmune thyroiditis (RR = 2.40) subjects vs matched controls. However, these risks appeared to be mitigated both in HUE (RR = 0.33) and autoimmune thyroiditis (RR = 0.78) subjects taking levothyroxine. Analyzing the duodenal microbiome, genus Neisseria was part of the core microbiome in the hypothyroid group (Hypo+/SIBO−, Hypo+/SIBO+) but not in nonhypothyroid subjects (Hypo−/SIBO−, Hypo−/SIBO+). Increased prevalence of Gram-negative coliforms occurred in both SIBO+ groups, but Escherichia/Shigella formed part of the core in nonhypothyroid subjects (Hypo−/SIBO+), whereas Klebsiella species were prevalent in hypothyroid group subjects with SIBO (Hypo+/SIBO+). Conclusion: These findings suggest there is an increased risk for development of SIBO in individuals with a history of hypothyroidism that may be ameliorated by treatment, and may involve specific Gram-negative coliforms.
- 5 September 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (3) , 707-720
Open AccessRelationship Between Hypothyroidism, Risk of Small Intestinal Bacterial Overgrowth, and Duodenal Microbiome Alterations
Context: There is an association between hypothyroidism and small intestinal bacterial overgrowth (SIBO), but the exact mechanistic link between these 2 conditions is not fully elucidated. Objective: We evaluate the incidence and risks of subsequently developing SIBO, and changes in small bowel microbial populations, in subjects with hypothyroidism or autoimmune thyroiditis. Design and Outcome Measures: Duodenal aspirates from REIMAGINE study subjects with a history of hypothyroidism (hypothyroid group, N = 49) and controls (N = 323) underwent 16S rRNA sequencing (MiSeq, Illumina); a subset also underwent metagenomic sequencing (NovaSeq6000, Illumina). Separately, the TriNetX Analytics platform was used to evaluate 10-year cumulative incidences and relative risk (RR) of developing SIBO in subjects with hypothyroidism (unspecified etiology [HUE]), and a subset with autoimmune thyroiditis, vs propensity score matched control groups. Results: Among REIMAGINE subjects, SIBO prevalence was higher in the hypothyroid group (32.65%) vs controls (15.17%). In the TriNetX analysis, 10-year cumulative incidences of SIBO were higher in HUE (RR = 2.20) and autoimmune thyroiditis (RR = 2.40) subjects vs matched controls. However, these risks appeared to be mitigated both in HUE (RR = 0.33) and autoimmune thyroiditis (RR = 0.78) subjects taking levothyroxine. Analyzing the duodenal microbiome, genus Neisseria was part of the core microbiome in the hypothyroid group (Hypo+/SIBO−, Hypo+/SIBO+) but not in nonhypothyroid subjects (Hypo−/SIBO−, Hypo−/SIBO+). Increased prevalence of Gram-negative coliforms occurred in both SIBO+ groups, but Escherichia/Shigella formed part of the core in nonhypothyroid subjects (Hypo−/SIBO+), whereas Klebsiella species were prevalent in hypothyroid group subjects with SIBO (Hypo+/SIBO+). Conclusion: These findings suggest there is an increased risk for development of SIBO in individuals with a history of hypothyroidism that may be ameliorated by treatment, and may involve specific Gram-negative coliforms.
- Open Access
- 26 June 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 70 (11) , 3846-3856
Hydrogen Sulfide and Methane on Breath Test Correlate with Human Small Intestinal Hydrogen Sulfide Producers and Methanogens
Background Evidence indicates that 3 gas breath testing (BT) correlates with stool microbial populations. Breath methane (CH4) levels correlate with stool Methanobrevibacter smithii levels and constipation, while hydrogen sulfide (H2S) levels correlate with stool H2S producers and diarrhea. However, their relationships to small bowel microbes are unknown. Aims To assess relationships between small bowel microbes and breath gases. Methods REIMAGINE study subjects completed a fasting single-sample BT for CH4 and H2S. During esophagogastroduodenoscopy without colon preparation, duodenal aspirates were obtained using double-lumen sterile aspiration catheters. Microbial DNAs underwent shotgun sequencing (NovaSeq6000). Results Duodenal bacterial profiles differed significantly in subjects with breath H2S ≥ 1.5 ppm vs. those with < 1.5 ppm, with 2.08-log2fold greater prevalence of phylum Thermodesulfobacteriota. Higher breath H2S levels correlated with greater duodenal prevalences of H2S producers, including Proteus mirabilis (P = 0.002), Desulfosarcina widdelii (P = 0.027), and Desulfobulbus oligotrophicus (P = 0.041); co-occurrence of all 3 species correlated with ~ 50% higher breath H2S levels (P = 0.0001). Duodenal archaeal profiles differed significantly in subjects with intestinal methanogen overgrowth (IMO, CH4 ≥ 10 ppm), with 2.94-log2fold greater prevalence of family Methanobacteriaceae vs. non-IMO subjects. Higher breath CH4 correlated with greater prevalences of methanogens including M. smithii (P = 0.02), Halarchaeum sp. CBA1220 (P = 0.003), Desulfurococcus mucosus (P = 0.046), and Halobaculum rubrum (P = 0.049). IMO was more common in subjects with co-occurrence of all 4 species (P = 0.04). In IMO-positive subjects, CH4 levels correlated with greater constipation severity (P = 0.019); P. mirabilis (P = 0.021) and D. oligotrophicus (P = 0.003) correlated with looser stool in IMO-negative subjects. M. smithii prevalence correlated with known hydrogen-producing syntrophs, e.g., Christensenella minuta (P < 0.001). Conclusion This study demonstrates that duodenal prevalences of H2S-producing bacteria and methanogenic archaea contribute to H2S and CH4 levels, respectively, on BT.
- 26 June 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 70 (11) , 3846-3856
Open AccessHydrogen Sulfide and Methane on Breath Test Correlate with Human Small Intestinal Hydrogen Sulfide Producers and Methanogens
Background Evidence indicates that 3 gas breath testing (BT) correlates with stool microbial populations. Breath methane (CH4) levels correlate with stool Methanobrevibacter smithii levels and constipation, while hydrogen sulfide (H2S) levels correlate with stool H2S producers and diarrhea. However, their relationships to small bowel microbes are unknown. Aims To assess relationships between small bowel microbes and breath gases. Methods REIMAGINE study subjects completed a fasting single-sample BT for CH4 and H2S. During esophagogastroduodenoscopy without colon preparation, duodenal aspirates were obtained using double-lumen sterile aspiration catheters. Microbial DNAs underwent shotgun sequencing (NovaSeq6000). Results Duodenal bacterial profiles differed significantly in subjects with breath H2S ≥ 1.5 ppm vs. those with < 1.5 ppm, with 2.08-log2fold greater prevalence of phylum Thermodesulfobacteriota. Higher breath H2S levels correlated with greater duodenal prevalences of H2S producers, including Proteus mirabilis (P = 0.002), Desulfosarcina widdelii (P = 0.027), and Desulfobulbus oligotrophicus (P = 0.041); co-occurrence of all 3 species correlated with ~ 50% higher breath H2S levels (P = 0.0001). Duodenal archaeal profiles differed significantly in subjects with intestinal methanogen overgrowth (IMO, CH4 ≥ 10 ppm), with 2.94-log2fold greater prevalence of family Methanobacteriaceae vs. non-IMO subjects. Higher breath CH4 correlated with greater prevalences of methanogens including M. smithii (P = 0.02), Halarchaeum sp. CBA1220 (P = 0.003), Desulfurococcus mucosus (P = 0.046), and Halobaculum rubrum (P = 0.049). IMO was more common in subjects with co-occurrence of all 4 species (P = 0.04). In IMO-positive subjects, CH4 levels correlated with greater constipation severity (P = 0.019); P. mirabilis (P = 0.021) and D. oligotrophicus (P = 0.003) correlated with looser stool in IMO-negative subjects. M. smithii prevalence correlated with known hydrogen-producing syntrophs, e.g., Christensenella minuta (P < 0.001). Conclusion This study demonstrates that duodenal prevalences of H2S-producing bacteria and methanogenic archaea contribute to H2S and CH4 levels, respectively, on BT.
- Open Access
- 5 June 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (3) , 745-753
The Safety of Pharmacotherapy for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
INTRODUCTION: Understanding the safety of pharmacotherapy for irritable bowel syndrome (IBS) enables individuals to make informed treatment decisions. While many studies include the number needed to treat to highlight therapeutic benefits, adding the number needed to harm (NNH), a measure we evaluate herein, could enable more comprehensive risk-benefit assessments. METHODS: PubMed, Web of Science, and Cochrane databases were searched through October 2024. Clinical trials investigating IBS pharmacotherapies including discontinuation rates because of adverse events (AEs) were included. Data were pooled using a random-effects model. The primary outcome was NNH for each pharmacotherapy, defined as the reciprocal of the absolute difference in risk of AEs leading to treatment discontinuation between the experimental and placebo groups. Secondary outcomes included the relative risk of withdrawing because of an AE and the most common AEs for each drug. RESULTS: Fifty-four trials met inclusion criteria. For constipation-predominant IBS pharmacotherapies, the NNH for linaclotide, lubiprostone, plecanatide, tegaserod, and tenapanor was 35 ( P < 0.01), 53 ( P = 0.59), 59 ( P < 0.01), 58 ( P = 0.03), and 16 ( P < 0.01), respectively. For diarrhea-predominant IBS pharmacotherapies, the NNH for alosetron and eluxadoline was 14 ( P < 0.01) and 32 ( P < 0.01) whereas the NNH for both rifaximin and ramosetron was a negative, although statistically insignificant, value. For IBS global symptom pharmacotherapies, the tricyclics, the NNH was 24 ( P < 0.01). Many AEs were transient without long-term sequela. DISCUSSION: Among pharmacotherapies for IBS, tricyclics (especially at elevated doses), tenapanor, and alosetron have the highest absolute risk of discontinuation because of an AE when compared with rifaximin, the safest pharmacotherapy studied.
- 5 June 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (3) , 745-753
Open AccessThe Safety of Pharmacotherapy for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
INTRODUCTION: Understanding the safety of pharmacotherapy for irritable bowel syndrome (IBS) enables individuals to make informed treatment decisions. While many studies include the number needed to treat to highlight therapeutic benefits, adding the number needed to harm (NNH), a measure we evaluate herein, could enable more comprehensive risk-benefit assessments. METHODS: PubMed, Web of Science, and Cochrane databases were searched through October 2024. Clinical trials investigating IBS pharmacotherapies including discontinuation rates because of adverse events (AEs) were included. Data were pooled using a random-effects model. The primary outcome was NNH for each pharmacotherapy, defined as the reciprocal of the absolute difference in risk of AEs leading to treatment discontinuation between the experimental and placebo groups. Secondary outcomes included the relative risk of withdrawing because of an AE and the most common AEs for each drug. RESULTS: Fifty-four trials met inclusion criteria. For constipation-predominant IBS pharmacotherapies, the NNH for linaclotide, lubiprostone, plecanatide, tegaserod, and tenapanor was 35 ( P < 0.01), 53 ( P = 0.59), 59 ( P < 0.01), 58 ( P = 0.03), and 16 ( P < 0.01), respectively. For diarrhea-predominant IBS pharmacotherapies, the NNH for alosetron and eluxadoline was 14 ( P < 0.01) and 32 ( P < 0.01) whereas the NNH for both rifaximin and ramosetron was a negative, although statistically insignificant, value. For IBS global symptom pharmacotherapies, the tricyclics, the NNH was 24 ( P < 0.01). Many AEs were transient without long-term sequela. DISCUSSION: Among pharmacotherapies for IBS, tricyclics (especially at elevated doses), tenapanor, and alosetron have the highest absolute risk of discontinuation because of an AE when compared with rifaximin, the safest pharmacotherapy studied.